Generics Win Two

February 2002
Pharmaceutical Executive;Feb2002, Vol. 22 Issue 2, p28
Trade Publication
Reports on a court ruling in favor of generics for American BioScience's Taxol. Plan of Ivax to pursue claims against American BioScience and BristolMyers Squibb.


Related Articles

  • Ivax Wins Round in Paclitaxel Patent Battle, Is Likely to Remain. Krause, Carey // Chemical Market Reporter;1/21/2002, Vol. 261 Issue 3, p12 

    Reports that Ivax Corp. has won a patent lawsuit battle with American BioSciences Inc. (ABI) at a federal district court in California over its paclitaxel, an anticancer generic drug. ABI plans on the court ruling; Competition in the United States paclitaxel market; Projected sales growth of...

  • Another Round in Ongoing Taxol Litigation.  // Chemical Market Reporter;11/13/2000, Vol. 258 Issue 20, p18 

    Reports on the preliminary injunction given by a United States (U.S.) federal district court to American BioScience Inc. regarding the lawsuit filed by Ivax Corporation in relation to Taxol drug.

  • Ivax, BMS Square Off Again in Taxol Battle.  // Chemical Market Reporter;10/09/2000, Vol. 258 Issue 15, p15 

    Unveils the lawsuit filed by Ivax Corp. against Bristol-Myers Squibb (BMS) Co. and American BioScience Inc. over anti-competitive practices concerning Bristol-Myers' Taxol. Background information of the lawsuit.

  • Ivax, BMS Suit Up In Taxol Legal Battle.  // Chemical Market Reporter;08/21/2000, Vol. 258 Issue 8, p20 

    Reports on the legal battle between Ivax Corporation and Bristol-Myers Squibb (BMS) over a generic version of Bristol-Myers' anti-cancer drug paclitaxel. Lawsuit filed by American BioScience Inc. against BMS; Details on American BioScience's motion for a preliminary injunction; Requirements...

  • IVAX GETS APPROVAL TO MARKET PAXENE IN CANADA.  // Worldwide Biotech;Jun2000, Vol. 12 Issue 6, p5 

    Reports that IVAX Corp. has received approval to market its propriety anti-cancer drug, Paxene (paclitaxel), in Canada for the treatment of AIDS-related Kaposi's sarcoma in patients who have failed prior liposomal anthracycline therapy.

  • Ivax Corp. Receives Patent for Oral Paclitaxel. Krause, Carey // Chemical Market Reporter;6/18/2002, Vol. 259 Issue 25, p12 

    Reports on the patent for an oral formulation of paclitaxel received by Ivax Corp. from the U.S. Patent and Trademark Office. Advantages offered by the oral form of paclitaxel; Predicted sales of the drug; Benefits of the oral form of paclitaxel in improving the market potential for Ivax.

  • Life Science Briefs.  // Chemical Market Reporter;09/18/2000, Vol. 258 Issue 12, p13 

    Covers news briefs on the pharmaceutical industry in the United States as of September 18, 2000. Delay of the expected merger of Glaxo Wellcome and SmithKline Beecham; Acquisition of Principia Pharmaceutical Corp. by Human Genome Sciences Inc.; Rejection of a federal appeals court on the...

  • Generics Watch.  // Drug Store News;1/17/2000, Vol. 22 Issue 1, p22 

    Presents news briefs on generic drugs in the United States (US) as of January 17, 2000. Launching of Teva's Diltiazem Extended Release Capsules for the treatment of hypertension and angina; Approval of the US Food and Drug Administration for IVAX Corp.'s ANDA for albuterol sulfate inhalation...

  • DRUGMAKERS FIGHT FOR GOOD NAME. Becker, Cinda // Modern Healthcare;8/27/2001, Vol. 31 Issue 35, p28 

    Deals with the challenges faced by drugmakers in seeking generic name products. Drop in the price of the sedative Versed manufactured by Roche; Discussion on the legal challenges; Competition faced by the drug Taxol from Bristol Myers Squibb.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics